Anixa Biosciences Inc. (ANIX)
3.05
-0.10 (-3.17%)
At close: Mar 03, 2025, 12:09 PM
No 1D chart data available
| Bid | 3.01 |
| Market Cap | 98.2M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -12.67M |
| EPS (ttm) | -0.39 |
| PE Ratio (ttm) | -7.82 |
| Forward PE | -7.78 |
| Analyst | Buy |
| Ask | 3.05 |
| Volume | 100,079 |
| Avg. Volume (20D) | 119,181 |
| Open | 3.12 |
| Previous Close | 3.15 |
| Day's Range | 3.00 - 3.15 |
| 52-Week Range | 2.07 - 4.20 |
| Beta | 0.93 |
About ANIX
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the t...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 7, 1983
Employees 5
Stock Exchange NASDAQ
Ticker Symbol ANIX
Website https://www.anixa.com
Analyst Forecast
According to 3 analyst ratings, the average rating for ANIX stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 227.87% from the latest price.
Buy 66.67%
Hold 0.00%
Sell 0.00%
1 month ago
+6.05%
Anixa Biosciences shares are trading higher. D Bor...
Unlock content with
Pro Subscription
1 month ago
+16.6%
Anixa Biosciences shares are trading higher after the company highlighted key business milestones for 2024 and outlined goals for the next year.
